Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Profile of a factor Xa inhibitor in development at Yamanouchi

May 6, 1998

FDA advisory committee recommends approval of Aggrastat

May 4, 1998

XR-300: in vitro and in vivo characterization of new antiplatelet/antithrombotic agent

May 4, 1998

Fraxiparine now listed on Canadian health plan formularies

April 30, 1998

Aspirin versus warfarin for the prevention of stroke in patients with atrial fibrillation

April 29, 1998

Phase I data reported for Vasoflux at ACC meeting in Rio

April 28, 1998

Orbofiban: a fibrinogen antagonist for the treatment of acute coronary syndromes

April 28, 1998

t-PA treatment may be beneficial to stroke patients and health care systems

April 28, 1998

New hirudin option now available in U.K.

April 27, 1998

Markers of thrombin and their relation to clinical outcome after myocardial infarction

April 23, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 8, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 8, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.